Research programme: stroke therapeutics - Astellas Pharma/Quark Pharmaceuticals

Drug Profile

Research programme: stroke therapeutics - Astellas Pharma/Quark Pharmaceuticals

Alternative Names: FR-210575; Stroke research programme - Astellas Pharma/Quark Pharmaceuticals

Latest Information Update: 19 Oct 2015

Price : $50

At a glance

  • Originator Astellas Pharma; Quark Biotech
  • Developer Astellas Pharma; SBI Biotech
  • Class Cinnamates; Small molecules; Triazines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Stroke

Most Recent Events

  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 11 Aug 2003 Quark and Fujisawa have extended their research collaboration
  • 06 Aug 2002 Preclinical trials in Stroke in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top